Imfinzi (durvalumab) - AstraZeneca
Imjudo (tremelimumab-actl) - AstraZeneca
AiTan (rivoceranib) - HLB Bio Group
Tecentriq (atezolizumab) - Roche
Avastin (bevacizumab) - Roche
Tevimbra (tislelizumab-jsgr) - BeOne Medicines
AiRuiKa (camrelizumab) - HLB Bio Group
https://journals.lww.com/hep/fulltext/2025/10001/the_liver_meeting__2025_abstracts.1.aspx
 
Luca Galbato Muscio1; Giorgia Pezzola1; Emanuela Di Giacomo1; Andrea Falcomatà2; Claudia Fulgenzi3; Giovanni Galati4; Paolo Gallo4; Giuseppina Pacella5; Gianluca Mascianà6; Rebecca Casati5; Gabriele D'Ercole7; Michele Fiore7; Giuseppe Tonini1; Antonio Picardi4; Rosario Francesco Grasso5; Marianna Silletta1
 
Oct 8, 2025
 
Next